Zifibancimig Biosimilar – Anti-ANG-2 and VEGFA mAb – Research Grade

Description of Zifibancimig Biosimilar - Anti-ANG-2 and VEGFA mAb - Research Grade

Zifibancimig Biosimilar – Anti-ANG-2 and VEGFA mAb – Research Grade: A Promising Therapeutic Antibody Targeting ANG-2 and VEGFA Zifibancimig Biosimilar, also known as Anti-ANG-2 and VEGFA mAb, is a novel therapeutic antibody that has shown great potential in targeting two important proteins, ANG-2 and VEGFA, involved in various diseases including cancer and inflammatory disorders. This biosimilar is a research grade product, meaning it is primarily used for preclinical and clinical research purposes.

Structure of Zifibancimig Biosimilar

Zifibancimig Biosimilar is a monoclonal antibody (mAb) that is designed to specifically bind to ANG-2 and VEGFA proteins. It is a fully humanized antibody, meaning it is derived from human cells and has a high affinity and specificity for its target proteins. The antibody has a molecular weight of approximately 150 kDa and is composed of two identical heavy chains and two identical light chains. The heavy chains are connected to each other by disulfide bonds, while the light chains are connected to the heavy chains by both disulfide bonds and non-covalent interactions.

The unique structure of Zifibancimig Biosimilar allows it to bind to ANG-2 and VEGFA with high specificity and block their activity, making it a potent therapeutic agent.

Activity of Zifibancimig Biosimilar

Zifibancimig Biosimilar exerts its activity by specifically binding to ANG-2 and VEGFA and inhibiting their functions. ANG-2 is a protein involved in angiogenesis, the process of forming new blood vessels, while VEGFA is a protein that promotes the growth and survival of blood vessels. Both of these proteins play crucial roles in tumor growth and progression, as well as in inflammatory disorders.

By binding to ANG-2 and VEGFA, Zifibancimig Biosimilar blocks their interactions with their respective receptors, preventing the activation of downstream signaling pathways that promote angiogenesis and inflammation. This leads to a decrease in tumor growth and inflammation, making Zifibancimig Biosimilar a promising therapeutic option for various diseases.

Application of Zifibancimig Biosimilar

Zifibancimig Biosimilar has shown promising results in preclinical studies for the treatment of various cancers, including lung, breast, and colon cancer. It has also shown potential in treating inflammatory disorders such as rheumatoid arthritis and psoriasis.

Due to its research grade status, Zifibancimig Biosimilar is primarily used for preclinical and clinical research purposes. It can be used in in vitro and in vivo studies to investigate the role of ANG-2 and VEGFA in disease progression and to evaluate the efficacy of Zifibancimig Biosimilar as a therapeutic agent.

Conclusion

Zifibancimig Biosimilar, also known as Anti-ANG-2 and VEGFA mAb, is a novel therapeutic antibody that specifically targets ANG-2 and VEGFA proteins. Its unique structure and mechanism of action make it a promising candidate for the treatment of various cancers and inflammatory disorders. As a research grade product, Zifibancimig Biosimilar is an important tool for preclinical and clinical research in understanding the role of ANG-2 and VEGFA in disease and developing effective treatments.